Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

JediGreen May. 22 at 7:11 PM

$BCTX This Is How The SMART Money Manipulates YOUR Trades! (Leaked Video) - YouTube https://www.youtube.com/watch?v=RKGaXB4AyWs

0 · Reply

ZacksResearch May. 22 at 6:37 PM

$BCTX just dropped survival data that could turn heads at ASCO 👀 📈 Phase 2 patients who started CPI in cycle 1 saw median OS of 13.3 months vs. 7.4 months with delayed CPI 🧬 The Phase 3-selected formulation delivered 16.6 months median OS with 52% 12-month survival ✅ No treatment-related discontinuations or unexpected safety signals reported BriaCell is also highlighting preserved quality of life and potential home self-administration in its ongoing Phase 3 Bria-ABC study — a big deal for heavily pretreated metastatic breast cancer patients. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38186&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38186

0 · Reply

SmallCapGrowth May. 22 at 6:12 PM

BB's Stock Haven : $BCTX is pleased to announce positive cl... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632559 via @Investors_Hub

0 · Reply

SmallCapGrowth May. 22 at 6:11 PM

Breaking: BriaCell $BCTX reports positive Bria-IMT™ data at ASCO 2026 — Phase 2 median OS 16.6 months & supportive Phase 3 QOL and biomarker findings. Full story: https://wix.to/gMgrDdd #ASCO2026 #Biotech #ClinicalTrials

0 · Reply

negligiblecat May. 22 at 5:52 PM

$BCTX Considering that they have virtually no money and that they have been guiding 2026 instead of 1h 26 as they originally did a few months back hints that its likely coming Q3 or Q4. Their cash will be very low by then so its not impossible they will have to dilute even more by then.

1 · Reply

SmallCapGrowth May. 22 at 5:31 PM

$BCTX BriaCell’s Bria‑IMT™ data at ASCO 2026 look promising — Phase 2 median OS 16.6 months, positive QOL in Phase 3, and biomarker confirmation of response predictors. Read more: https://wix.to/k2eI7hA #BCTX #ASCO2026 #oncology

0 · Reply

SmallCapGrowth May. 22 at 4:59 PM

which one is next? : $BCTX BriaCell at ASCO 2026: Bria-IMT https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632815 via investorshub

0 · Reply

SmallCapGrowth May. 22 at 4:41 PM

$BCTX BriaCell at ASCO 2026: Bria-IMT™ shows a Phase 2 median OS of 16.6 months and positive Phase 3 QOL data in heavily pre-treated MBC patients. Biomarker analyses support response predictors. Full story: https://wix.to/X0GjMKI #ASCO2026 #BriaCell #BioTech #CancerResearch

0 · Reply

SmallCapGrowth May. 22 at 4:31 PM

MOMO'S BREAKOUT BOARD : Smart money watches inflection points. $BCTX:.... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632652 via @Investors_Hub

1 · Reply

_rags_2_riches_ May. 22 at 4:29 PM

$BCTX Momentum downward. Subpar results especially when compared to its peer group.

3 · Reply

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 13 hours ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 14 hours ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 7 days ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 8 days ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 8 days ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 9 days ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 9 days ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 9 days ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 10 days ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 15 days ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 15 days ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 16 days ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 25 days ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 4 weeks ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 4 weeks ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 4 weeks ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 4 weeks ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 7 weeks ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 2 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 2 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 2 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 3 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 3 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Wed, 18 Feb 2026 17:30:00 -0500 - 3 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 3 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

Tue, 17 Feb 2026 07:30:00 -0500 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T12:40:40.000Z - 4 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Wed, 28 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T12:41:04.000Z - 4 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Tue, 27 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 4 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 4 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 4 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 4 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 4 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 4 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:41:11.000Z - 4 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 4 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:08:02.000Z - 4 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 4 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

Jan 13, 2026, 7:30 AM EST - 4 months ago

Market Cap	28.13M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	491,900
Avg Vol	206,678
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	54%
Beta	1.26
Analysts	Strong Buy
Price Target	$40.00